EP3976001A4 - Tablettenformulierungen von apremilast - Google Patents

Tablettenformulierungen von apremilast Download PDF

Info

Publication number
EP3976001A4
EP3976001A4 EP20813638.2A EP20813638A EP3976001A4 EP 3976001 A4 EP3976001 A4 EP 3976001A4 EP 20813638 A EP20813638 A EP 20813638A EP 3976001 A4 EP3976001 A4 EP 3976001A4
Authority
EP
European Patent Office
Prior art keywords
apremilast
tablet formulations
formulations
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20813638.2A
Other languages
English (en)
French (fr)
Other versions
EP3976001A1 (de
Inventor
Gulcin TOK
Ediz Yildirim
Merve USTUN OZDEMIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3976001A1 publication Critical patent/EP3976001A1/de
Publication of EP3976001A4 publication Critical patent/EP3976001A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
EP20813638.2A 2019-05-31 2020-04-15 Tablettenformulierungen von apremilast Pending EP3976001A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/08440A TR201908440A2 (tr) 2019-05-31 2019-05-31 Apremi̇lastin tablet formülasyonlari
PCT/TR2020/050318 WO2020242414A1 (en) 2019-05-31 2020-04-15 Tablet formulations of apremilast

Publications (2)

Publication Number Publication Date
EP3976001A1 EP3976001A1 (de) 2022-04-06
EP3976001A4 true EP3976001A4 (de) 2023-04-26

Family

ID=73553856

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20813638.2A Pending EP3976001A4 (de) 2019-05-31 2020-04-15 Tablettenformulierungen von apremilast

Country Status (3)

Country Link
EP (1) EP3976001A4 (de)
TR (1) TR201908440A2 (de)
WO (1) WO2020242414A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183389A1 (de) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Apremilast enthaltende pharmazeutische zusammensetzung
CN114533691A (zh) * 2022-03-21 2022-05-27 成都百裕制药股份有限公司 一种阿普米司特片剂及其工业化制备方法
CN116531326B (zh) * 2023-04-26 2023-11-14 广东嘉博制药有限公司 一种阿普米司特的口服乳剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083348A1 (en) * 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10774042B2 (en) * 2016-05-12 2020-09-15 Zaklady Farmaceutyczne Polpharma Sa Crystalline forms of apremilast
CN107115310A (zh) * 2017-04-12 2017-09-01 广州艾格生物科技有限公司 一种阿普斯特口服固体制剂及其制备方法
WO2019073477A1 (en) 2017-10-10 2019-04-18 Mankind Pharma Ltd. PHARMACEUTICAL COMPOSITION OF APREMILAST WITH EXTENDED RELEASE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083348A1 (en) * 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof

Also Published As

Publication number Publication date
TR201908440A2 (tr) 2020-12-21
WO2020242414A1 (en) 2020-12-03
EP3976001A1 (de) 2022-04-06

Similar Documents

Publication Publication Date Title
EP3582755A4 (de) Formulierungen
EP4045480A4 (de) Pharmazeutische formulierungen
EP3509581A4 (de) Formulierungen von (r
EP4125815A4 (de) Therapeutische zusammensetzungen
EP3976001A4 (de) Tablettenformulierungen von apremilast
EP3853204A4 (de) Verbesserte und stabile pharmazeutische apremilast-zusammensetzungen
EP3810118A4 (de) Formulierungen von tegavivint und verwandten verbindungen
EP3873444A4 (de) Therapeutische verbindungen und zusammensetzungen
EP3917910A4 (de) Therapeutische verbindungen und zusammensetzungen
EP3868371A4 (de) Neuartige pharmazeutische zusammensetzung
EP3851121A4 (de) Pharmazeutische zusammensetzung mit menschlichen monoklonalen anti-il-33-antikörpern
EP4007590A4 (de) Dihydrohonokiol enthaltende formulierungen
EP3886820B8 (de) Kapselformulierungen
EP3873446A4 (de) Therapeutische verbindungen und zusammensetzungen
EP3755376A4 (de) Formulierungen mit mucin-beeinträchtigenden proteasen
EP3716766A4 (de) Benzoxaborolverbindungen und deren formulierungen
EP3582748A4 (de) Sulfatfreie formulierungen
EP3801532A4 (de) Formulierungen von raltegravir
EP3881841A4 (de) Pharmazeutische zusammensetzung
EP3810137A4 (de) Nitroimidazol-formulierungen
EP3746080A4 (de) Pharmazeutische formulierungen
EP3749662A4 (de) Therapeutische verbindungen und zusammensetzungen
EP3554508A4 (de) Pharmazeutische formulierungen von suvorexant
EP4013441A4 (de) Larazotid-formulierungen
EP3984549A4 (de) Medizinische zusammensetzung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230323

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/28 20060101ALI20230317BHEP

Ipc: A61P 19/02 20060101ALI20230317BHEP

Ipc: A61K 31/4035 20060101ALI20230317BHEP

Ipc: A61K 9/20 20060101AFI20230317BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708